Erman, Mustafa
Biswas, Bivas
Danchaivijitr, Pongwut
Chen, Lingwu
Wong, Yoke Fui
Hashem, Tarek
Lim, Chun Sen
Karabulut, Bulent
Chung, Hsiao-Jen
Chikatapu, Chandrasekhar
Ingles, Sara
Slimane, Khemaies
Kanesvaran, Ravindran
Article History
Received: 20 April 2021
Accepted: 28 August 2021
First Online: 14 September 2021
Change Date: 9 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12885-021-08848-8
Declarations
:
: The research was conducted ethically in accordance with the World Medical Association.Declaration of Helsinki International Conference on Harmonisation Good Clinical Practice, patient privacy requirements, and ethical principles outlined in the Declaration of Helsinki.2018. The protocol and ICF were reviewed and approved in Singapore by “Singhealth Centralised Institutional Review Board (CIRB)”, and also by properly constituted Institutional Review Boards/Independent Ethics Committees (IRB/IEC) of 34 other participating centres according to local regulations before the start of the study. Health authority approval was obtained per local regulations. Patients provided informed consent according to local requirements.
: Not Applicable.
: ME reports honoraria from Novartis, Pfizer, Astellas, Janssen, BMS, MSD, Amgen, Nobel, Astra-Zeneca, Roche, and Gen Ilac outside the submitted work; TH is a member of advisory board, consultant and speaker for Hoffman la Roche, Novartis, Astra Zeneca, MSD, Amgen, Pfizer, Janssen Cilag, Merck Serono, and Mundi Pharma; BK reports clinical trials, satellite symposiums, congress and journal support from Roche, Pfizer, Novartis, Merck, Serono, MSD, Amgen, Bayer, Gen, BMS, and AstraZeneca; RK reports grants and personal fees from Eisai, Ipsen, BMS, MSD, Pfizer, Astellas, Johnson & Johnson, Amgen, Sanofi, and Mundipharma outside the submitted work; Sara Ingles is employed by Aerotek and contracted by Novartis AG; KS is an employee of Novartis and owner of stock options; CC is an employee of Novartis AG; BB, PD, LC, YFW, CSL, and HJC have declared that they have no competing interests.